Parenteral Drugs (India) (NSE:PDPL) Total Stockholders Equity: ₹-8,240.31 Mil (As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Total Stockholders Equity?

Parenteral Drugs (India) NSE:PDPL 4 Total Stockholders Equity is ₹-8,240.31 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Total Stockholders Equity for the quarter that ended in Mar. 2022 was ₹-8,240.31 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Parenteral Drugs (India)'s Book Value per Share for the quarter that ended in Mar. 2022 was ₹-276.37. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Parenteral Drugs (India)'s Debt-to-Equity for the quarter that ended in Mar. 2022 was -0.13.

Parenteral Drugs (India)  (NSE:PDPL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Parenteral Drugs (India)'s Book Value per Share for the quarter that ended in Mar. 2022 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-8240.306-0)/29.816
=-276.37

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Parenteral Drugs (India)'s Debt-to-Equity for the quarter that ended in Mar. 2022 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 1071.994) / -8240.306
=-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Total Stockholders Equity Related Terms

Parenteral Drugs (India) Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Total Stockholders Equity Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,364.37 -4,469.21 -5,613.06 -6,828.77 -8,240.31

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,828.77 0.00 -7,485.04 0.00 -8,240.31
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of ₹-8,240.31 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Total Stockholders Equity of ₹-8,240.31 Mil as of Mar. 2022. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Total Stockholders Equity too high?
Parenteral Drugs (India)'s current Total Stockholders Equity is ₹-8,240.31 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Total Stockholders Equity compare to ZTS and CTLT?
Parenteral Drugs (India)'s Total Stockholders Equity of ₹-8,240.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Total Stockholders Equity is ₹-8,240.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Total Stockholders Equity of ₹-8,240.31 Mil. The current Total Stockholders Equity is ₹-8,240.31 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Total Stockholders Equity is ₹-8,240.31 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price